Jun 27, 2026
15 MIN READ

Does Wegovy Help with Weight Loss? What You Need to Know

Semaglutide injections have demonstrated significant weight loss results in clinical trials, helping patients lose up to 15% of body weight. PlexusDx offers compounded semaglutide starting at $149 per month, accessible nationwide without insurance requirements.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →

Jun 27, 2026
15 MIN READ

does wegovy help with weight loss? what you need to know — PlexusDx GLP-1 education

Last reviewed: June 27, 2026

Last updated: June 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that has gained widespread attention for weight management. Clinical trials show patients using semaglutide lose an average of 12–15% of their starting body weight over 68 weeks. PlexusDx provides access to compounded semaglutide injections manufactured by licensed 503A pharmacies, offering an alternative pathway to GLP-1 therapy without insurance barriers.

How Semaglutide Injections Support Weight Loss

Semaglutide works by activating GLP-1 receptors in the brain that regulate hunger, fullness signals, and blood sugar control. When these receptors are stimulated, patients typically experience reduced appetite, slower stomach emptying, and improved satiety—meaning they feel fuller longer and consume fewer calories naturally. The medication does not force weight loss; instead, it recalibrates the body's appetite regulation system to make sustainable eating patterns easier.

The weight loss process with semaglutide is gradual and dose-dependent. Most patients begin with a low starting dose and increase incrementally over weeks or months to minimize side effects and allow the body to adapt. Studies show that weight reduction accelerates between weeks 4 and 16, with continued progress through week 68 of treatment. After reaching a therapeutic dose, many patients maintain steady weight loss without further dose increases, demonstrating that the medication's benefit stabilizes over time.

Clinical Evidence Behind Semaglutide for Weight Management

The landmark STEP trials, conducted between 2019 and 2021, evaluated semaglutide's effectiveness in over 4,500 participants without diabetes. Participants receiving semaglutide at 2.4 mg weekly lost an average of 15% body weight compared to 2.6% in the placebo group—a difference of approximately 35 pounds for a 230-pound person. Results were consistent across age groups, ethnicities, and baseline weight categories, indicating that semaglutide's effect is broadly applicable rather than limited to specific populations.

Cardiovascular outcomes also improved in clinical data. The SUSTAIN-6 trial demonstrated that semaglutide reduces the risk of major cardiovascular events by 26% in patients with type 2 diabetes and established heart disease. While most patients using semaglutide for weight loss do not have diabetes, this evidence reinforces that GLP-1 therapy offers metabolic benefits beyond appetite suppression, including improved insulin sensitivity and inflammation markers.

Semaglutide vs. Other GLP-1 Weight Loss Options

Semaglutide is one of several GLP-1 receptor agonists available for weight management, alongside tirzepatide (which targets both GLP-1 and GIP receptors) and liraglutide. Tirzepatide produces slightly greater average weight loss—up to 21% body weight in clinical trials—because it activates two hormone pathways rather than one. However, semaglutide remains a highly effective first-line option and is often preferred for patients seeking a well-studied, single-pathway medication with a once-weekly injection schedule.

PlexusDx offers both compounded semaglutide injections starting at $149 per month and compounded tirzepatide injections starting at $249 per month, allowing patients to choose based on clinical goals, tolerance, and personal preference. The choice between them should be made in consultation with a healthcare provider who can assess individual metabolic factors and prior medication responses. PlexusDx also provides the Precision Peptide Genetic Test as an add-on to help identify which GLP-1 pathway may be most effective for each patient's unique genetic profile.

What to Expect: Timeline, Side Effects, and Results

Most patients notice appetite reduction within the first 1–2 weeks of semaglutide, though weight loss typically becomes measurable around week 4. The most common side effects are gastrointestinal—including nausea, constipation, and diarrhea—which affect 25–50% of users and tend to improve as the body adapts over 2–4 weeks. Staying hydrated, eating slowly, and consuming smaller, balanced meals can reduce these symptoms. Serious side effects are rare but include pancreatitis symptoms (severe abdominal pain) and vision changes; patients should report these immediately to their healthcare provider.

Long-term success with semaglutide depends on consistent use and lifestyle support. Weight loss plateaus around week 16–20 for many patients, then resumes as doses increase. Most patients who maintain treatment for 52 weeks continue to lose weight gradually, with total losses ranging from 10–35% of starting body weight depending on baseline weight, genetics, and adherence. Upon discontinuation, gradual weight regain typically occurs over 6–12 months, which is why semaglutide is most effective as a long-term management tool rather than a short-term intervention.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide from PlexusDx the same as prescription Wegovy?

PlexusDx semaglutide is compounded by licensed 503A pharmacies using the same active ingredient as Wegovy but at a lower cost—starting at $149 per month. Compounded medications are not FDA-approved branded products, but they follow strict quality and sterility standards. Your healthcare provider can discuss whether compounded or brand-name options are appropriate for your situation.

How much weight can I realistically lose with semaglutide?

Clinical trials show average weight loss of 12–15% of body weight over 68 weeks, though individual results vary based on genetics, lifestyle, starting weight, and adherence. Some patients lose 10% while others achieve 20%+ losses. PlexusDx's Precision Peptide Genetic Test can identify genetic predispositions to GLP-1 response, helping predict your potential outcome.

Do I need insurance to start semaglutide with PlexusDx?

No. PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization. Semaglutide injections start at $149 per month and are HSA/FSA eligible, making them accessible regardless of insurance status.

What happens if I stop taking semaglutide?

Weight typically begins to regain gradually over 6–12 months after stopping semaglutide because appetite regulation returns to baseline. This is why semaglutide is considered a long-term tool for weight maintenance rather than a temporary fix. Many patients find that combining medication with sustained lifestyle changes helps minimize regain.

Can the Precision Peptide Genetic Test tell me if semaglutide will work for me?

PlexusDx's Precision Peptide Genetic Test identifies key genetic variants in GLP1R, GIPR, FTO, and MC4R pathways that influence appetite regulation and GLP-1 responsiveness. While genetics don't guarantee results, the test maps 14 pathways and 150+ insights to help your provider personalize whether semaglutide, tirzepatide, or combination therapy may be optimal for your biology. The test costs $99 as an add-on after your first month of treatment.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves